Kolexia
Sarabi Matthieu Gastro-entérologie
Sarabi Matthieu
Gastro-entérologie
Cabinet libéral
Rillieux-la-Pape, France
91 Activités
182 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Adénocarcinome Tumeurs colorectales Tumeurs du pancréas Tumeurs des canaux biliaires Cholangiocarcinome Métastase tumorale Lupus érythémateux disséminé Carcinome du canal pancréatique Inflammation

Collaborateurs

Voir plus
De La Fouchardiere Christelle
De La Fouchardiere Christelle
Centre Paoli-Calmettes, Marseille, France
Desseigne Francoise
Desseigne Francoise
Centre Léon-Bérard, Lyon, France
Rochefort Pauline
Rochefort Pauline
Centre Léon-Bérard, Lyon, France
Artru Pascal
Artru Pascal
Hopital Prive De L'est Lyonnais (hpel), Saint-Priest, France

Industries

Voir plus
B3TSI
22 collaboration(s)
Dernière en 2022
Servier
10 collaboration(s)
Dernière en 2022
M3 Global Research Ltd
6 collaboration(s)
Dernière en 2023
EXAFIELD
3 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
PROFILER: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Essai Clinique (Centre Léon-Bérard)   01 mars 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
European journal of cancer (Oxford, England : 1990)   06 février 2024
121P PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
New drug approval: Durvalumab in combinaison with cisplatin and gemcitabine in first-line in patient with advanced biliary tract cancer.
Bulletin du cancer   17 mai 2023
COLON-IM : Microbiota and Immune Infiltrate in Normal, Dysplastic and Neoplastic Colorectal Tissue
Essai Clinique (Centre Léon-Bérard)   12 mai 2023
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
European journal of cancer (Oxford, England : 1990)   12 novembre 2022
A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3.
Journal of personalized medicine   12 avril 2022
Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer.
Journal for immunotherapy of cancer   04 janvier 2022
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.
Frontiers in oncology   24 septembre 2021